Breaking News
November 17, 2018 - FDA announces new actions to limit sale of e-cigarettes to youth
November 17, 2018 - Warmer winter temperatures related to higher crime rates
November 17, 2018 - MCO places increasing emphasis on helping people find and access healthy food
November 17, 2018 - Group of students aim to improve malaria diagnosis using old smartphones
November 17, 2018 - Transplantation of feces may protect preterm children from deadly bowel disease
November 17, 2018 - Researchers explore whether low-gluten diets can be recommended for people without allergies
November 17, 2018 - New and better marker for assessing patients after cardiac arrest
November 17, 2018 - For 7-year-old with failing bone marrow, a life-saving transplant | News Center
November 17, 2018 - New first-line treatment for peripheral T-cell lymphoma approved by FDA
November 17, 2018 - Artificial intelligence could be valuable tool to help young victims disclose traumatic testimony
November 17, 2018 - Breakthrough in the treatment of Restless Legs Syndrome
November 16, 2018 - FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
November 16, 2018 - Eagle Books | Native Diabetes Wellness Program
November 16, 2018 - Patients with common heart failure more likely to have lethal heart rhythms
November 16, 2018 - How AI could help veterinarians code their notes | News Center
November 16, 2018 - Bias-based bullying does more harm to students than generalized bullying
November 16, 2018 - Researchers find first direct evidence that cerebellum plays role in cognitive functions
November 16, 2018 - Non-coding genetic variant plays key role in endothelial function and disease incidence
November 16, 2018 - EMA recommends first all-oral treatment to tackle deadly sleeping sickness
November 16, 2018 - Drug used to treat dizziness may slow down growth of triple-negative breast cancer
November 16, 2018 - AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides
November 16, 2018 - ‘Orphan’ RNAs make cancer deadlier, but potentially easier to diagnose
November 16, 2018 - Air Cube touches down at hospital | News Center
November 16, 2018 - CRISPR-based tool shown to enhance cell-based immunotherapy
November 16, 2018 - Mechanisms that govern HIV latency differ in the gut and blood, finds study
November 16, 2018 - Researchers unravel mystery of NPM1 protein in acute myeloid leukemia
November 16, 2018 - High school students less likely to select milk, fruit for lunch when fruit juice is available
November 16, 2018 - Football coaches with great emotional competence are more successful
November 16, 2018 - Researchers awarded $10 million grant to address root causes of asthma in Puerto Rico
November 16, 2018 - Health Tip: Manage Morning Sickness
November 16, 2018 - Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
November 16, 2018 - ACC Latin America Conference brings experts to discuss latest cardiovascular science
November 16, 2018 - Pooled analysis of Intersect ENT’s steroid releasing implants in patients after frontal sinus surgery to be published
November 16, 2018 - Expectations about pain intensity can become self-fulfilling prophecies
November 16, 2018 - NIH awards $3.4 million to UC researchers to study gastrointestinal lymphatic system
November 16, 2018 - Highlighting Advances in Bioengineering and Analytical Technologies with eBooks
November 16, 2018 - Scientist Dr David Taylor of MR Solutions is a finalist in the BMW i UK Tech Founder Awards
November 16, 2018 - Earlier treatment could help reverse autistic-like behavior in tuberous sclerosis
November 16, 2018 - Sucking your baby’s pacifier could improve their health
November 16, 2018 - Vegetables and salad may include bacteria that are resistant to antibiotics
November 16, 2018 - Autism linked to prolonged connection between brain regions
November 16, 2018 - Endocrine Society chooses four Diabetes Caucus leaders as winners of Diabetes Champion Award
November 16, 2018 - Brain and muscle cells found within kidney organoids
November 16, 2018 - Person’s sex hormones may play key role in trauma survival, finds study
November 16, 2018 - PTEN Genetic Test: MedlinePlus Lab Test Information
November 16, 2018 - Toxic metal pollution linked with development of autism spectrum disorder
November 16, 2018 - Calcified nodules in the retina increase risk for progression to late stages of AMD
November 16, 2018 - ZEISS teams up with arivis AG to offer complete 3D imaging solutions
November 16, 2018 - Georgia State professor receives $1.2 million grant to study how the brain controls eating behavior
November 16, 2018 - Specific bacterial toxins reduce number of cells suppressing immune response
November 16, 2018 - Review by ID physician improves outcomes for outpatient parenteral antimicrobial therapy
November 16, 2018 - Conditions that produce signs similar to arthritis
November 16, 2018 - New artificial intelligence-based method predicts treatment effectiveness
November 16, 2018 - AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
November 16, 2018 - Surgery remains best treatment for appendicitis, Stanford study finds
November 16, 2018 - Non-surgical fistula creation system Ellipsys becomes key focus of attention at CiDA
November 16, 2018 - Researchers find no link between ‘allergy friendly’ dogs and lower risk of asthma
November 16, 2018 - Researchers elucidate new rules of connectivity of neurons in the neocortex
November 16, 2018 - Treating children with ‘bubble baby disease’
November 16, 2018 - Nexus announces availability of Arsenic Trioxide Injection in the US
November 16, 2018 - Researchers find metabolite shuttle between cells in the liver that may combat tissue fibrosis
November 16, 2018 - AHA: PTSD Common Among Those Who Suffer Tear in the Aorta’s Wall
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer

image_pdfDownload PDFimage_print

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression.

Studies have shown reduced recurrence and breast cancer mortality with zoledronic acid plus hormonal therapy in HR+ breast cancer in postmenopausal women, but the benefit in premenopausal women was previously less clear. Zoledronic acid is a bisphosphonate that reduces the rate of bone turnover; it is licensed to treat osteopororosis and to reduce bone damage in advanced cancers involving bone and hypercalcemia in cancer. Unlike tamoxifen, which blocks estradiol binding to the estrogen receptor, letrozole is an aromatase inhibitor that profoundly suppresses estradiol levels but has not previously been evaluated in premenopausal breast cancer.

The HOBOE-2 (Hormonal BOne Effects-2) phase 3 trial included 1065 patients with estrogen/progesterone receptor positive early breast cancer who had their last period within one year of randomization. They were treated with the gonadotrophin-releasing hormone agonist triptorelin (3.75mg every four weeks) for five years up to the age of 55 to suppress ovarian function and nearly two-thirds (63%) received chemotherapy before randomization.

The patients were randomized to hormonal therapy with tamoxifen (20mg/day) or letrozole (2.5mg/day) or to combination therapy with zoledronic acid (4mg IV every six months) plus letrozole (2.5mg/day) (ZL) for a planned treatment duration of five years. The study was stopped early in May 2018 after a median follow-up of 65 months when the Independent Monitoring Committee recommended sharing the data with the Early Breast Cancer Trialists’ Cooperative Group (EBCTCG) 2018 overview.

Results reported at ESMO 2018 showed there were 32 breast cancer recurrences or second breast or non-breast cancers or deaths in patients treated with ZL, giving a 5-year disease-free survival (DFS) probability of 0.93. There were 58 events in patients treated with tamoxifen and 44 events in the letrozole group, giving 5-year DFS event rates of 0.85 and 0.93, respectively (p=0.008).

Disease-free survival was significantly improved in patients randomized to zoledronic acid plus letrozole compared to those treated with tamoxifen, with an absolute advantage of 8% in 5-year DFS. The risk of breast cancer recurrence or non-cancer death was nearly halved in patients treated with ZL compared to those treated with T (hazard ratio [HR] 0.52, 95% confidence interval 0.34-0.80, p=0.003).

The improvement in DFS with ZL compared to tamoxifen was seen in all subgroups of patients apart from the small subgroup of women with tumors overexpressing HER2 who showed greater benefit with tamoxifen (interaction p=0.002).

There was no statistically significant difference in DFS comparing letrozole with tamoxifen (HR 0.72, 95% CI 0.48-1.07, p=0.06) or comparing ZL with letrozole alone (HR 0.70, 95% CI 0.44-1.12, p=0.22).

As expected, side-effects were more frequent in patients treated with ZL, with 9% of patients experiencing grade 3-4 toxicity compared to 4% of those treated with T and 7% of those treated with L. Nearly one in five (17%) patients treated with ZL stopped treatment before 5 years due to toxicity or refusal, compared to 7% of those on T and 7% of those on L. Among the most feared side-effects associated with the study drugs, there were four cases of jaw osteonecrosis in the ZL arm.

“HOBOE-2 strongly supports the hypothesis that combination treatment with an aromatase inhibitor and bisphosphonate plus triptorelin may improve prognosis in premenopausal patients with HR-positive breast cancer,” said lead author Prof. Francesco Perrone, Director of the Clinical Trials Unit at the Istituto Nazionale Tumori, Naples, Italy.

Perrone continued: “We had previously shown that, in combination with triptorelin, letrozole suppresses estradiol levels much more than tamoxifen in premenopausal patients. And we know that suppressing estradiol levels means cutting the fuel to endocrine-dependent breast cancer.”

Considering zoledronic acid, Perrone said: “Our hypothesis is that the drug modifies the bone microenvironment that is the niche where breast cancer micrometastases remain in a state of dormancy, potentially for many years. Microenvironment modifications may be lethal for isolated cancer cells, reducing the risk of distant metastases over time.” He explained: “The two mechanisms are partially independent and, therefore, may sum up to give an additive benefit.”

Reviewing the potential impact on clinical practice, Perrone suggested: “If the size of the benefit we saw is confirmed with longer follow-up, ZL treatment might turn out to be a highly cost-effective treatment for premenopausal HR+ breast cancer.” He noted that zoledronic acid and letrozole are both very cheap drugs, so could be used widely.

Commenting on the study for ESMO, Robert Coleman, Emeritus Professor of Medical Oncology, University of Sheffield, UK, said: “The findings add to existing information to support the use of more intensive treatment with an aromatase inhibitor and bisphosphonate in women at high risk for recurrence, either by virtue of node involvement or high-grade or large tumors.” He noted: “Both treatments add toxicity over and above tamoxifen and so are best limited to women at intermediate to high risk where the risk-benefits are likely to be acceptable.”

Coleman cautioned that the study was underpowered, with insufficient events for statistical confidence in the results. He added: “This study is not definitive but adds to the information on these two treatment approaches and will contribute to the ongoing EBCTCG meta-analyses.” He considered there were unlikely to be further trials with aromatase inhibitors and bisphosphonates as the focus is now on adding other targeted treatments.

Source:

https://www.esmo.org/Press-Office/Press-Releases/HOBOE-breast-cancer-Triptorelin-Perrone

Tagged with:

About author

Related Articles